Mentions
Extended reach
Total likes
Video views
AI synopsis
The discussion collectively conveys strong approval and high interest, with posts describing the drug Gleevec's success in achieving remission for CML patients and noting its potential to revolutionize treatment, using words like 'breakthrough' and 'full remission' to underscore its importance and influence.
Most discussions highlight the groundbreaking effectiveness of the drug in treating CML, with phrases like 'result in full remission' and 'breakthrough' indicating strong support.
Participants show high curiosity and admiration for the research, referencing the drug's success and potential, signaling a deep interest in the topic.
Some comments discuss specific mechanisms, trial phases, and broader implications, reflecting thoughtful and detailed engagement.
Numerous posts emphasize the potential for this drug to change cancer treatment paradigms, describing it as a 'game changer' and discussing its significance for patient outcomes.
يسميه البعض الدواء المعجزة!(imatinib) حوّل المرض الذي كان قاتلا يوم من الأيام (CML) إلى مرض سهل التحكّم به الدراسة الأولى التي اثبتت فعالية الدواء (الرابط) كانت مدعومة من شركة أدوية مما يعكس دور شركات الأدوية في دعم البحث العلمي في تخصص حساس مثل الأورام https://t.co/dDXGosvabo
@leslievosshall The phase 1 in CML patients is a #Singleplot in and of itself. https://t.co/I2LPFfeIWX https://t.co/QVviMqkY0g
The hunt for a specific anti-cancer drug continued. Then, a breakthrough: CGP57148B (aka Gleevec) was shown to result in full remission for nearly all chronic myeloid leukaemia patients
@DrKateLurain @adamcifu ...RCTs have to start somewhere https://t.co/ze9bsk9HeT
In this video, we explore the 2001 clinical trial that established Imatinib as the first effective targeted therapy for CML, revolutionizing cancer treatment by specifically inhibiting BCR-ABL tyrosine kinase and…
This video explores the 2001 clinical trial that revolutionized cancer therapy by demonstrating the efficacy and safety of Imatinib, a targeted BCR-ABL kinase inhibitor, in chronic myeloid leukemia, marking a major…
In this video, we examine a pioneering 2001 clinical trial that demonstrated the efficacy and safety of BCR-ABL kinase inhibitors like Imatinib in treating CML, leading to sustained blood count normalization and a shift…
In this video, we explore the 2001 clinical trial that established Imatinib as the first effective targeted therapy in chronic myeloid leukemia, marking a paradigm shift in cancer treatment by focusing on precision…
This video explores the 2001 clinical trial that established Imatinib as the first effective targeted therapy for CML, demonstrating high efficacy and safety in reducing cancer progression through BCR-ABL kinase…
This video discusses the 2001 clinical trial that established Imatinib as a targeted therapy for CML, showing high efficacy, safety, and its role in shifting to precision oncology. It explains how BCR-ABL inhibition…
This video explores the pivotal 2001 clinical trial that revolutionized oncology, demonstrating the efficacy and safety of the BCR-ABL inhibitor Imatinib in treating chronic myeloid leukemia, marking a shift toward…
This video discusses the 2001 clinical trial that established Imatinib as the first effective targeted therapy for CML, demonstrating high efficacy and safety by inhibiting BCR-ABL kinase activity and revolutionizing…
The hunt for a specific anti-cancer drug continued. Then, a breakthrough: CGP57148B (aka Gleevec) was shown to result in full remission for nearly all chronic myeloid leukaemia patients
@leslievosshall The phase 1 in CML patients is a #Singleplot in and of itself. https://t.co/I2LPFfeIWX https://t.co/QVviMqkY0g
يسميه البعض الدواء المعجزة!(imatinib) حوّل المرض الذي كان قاتلا يوم من الأيام (CML) إلى مرض سهل التحكّم به الدراسة الأولى التي اثبتت فعالية الدواء (الرابط) كانت مدعومة من شركة أدوية مما يعكس دور شركات الأدوية في دعم البحث العلمي في تخصص حساس مثل الأورام https://t.co/dDXGosvabo
@DrKateLurain @adamcifu ...RCTs have to start somewhere https://t.co/ze9bsk9HeT